Drugs / NORA520
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06285916 | Mar 2024 → Sep 2025 | postpartum depression | DuKang Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NORA520 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06285916 ↗ |
| Route | Oral | “Oral NORA520 tablets Dose 1 for 3 days” NCT06285916 ↗ |